In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone

Drug Metabolism and Disposition

Volumn 38, Issue 5, 2010, Pages 801-807

  Tong, Zeen ^a   Chandrasekaran, Appavu ^a   Li, Hongshan ^a   Rotshteyn, Yakov ^b   Erve, John C L ^a   DeMaio, William ^a   Talaat, Rasmy ^a   Hultin, Theresa ^a   Scatina, JoAnn ^a  

^a PFIZER INC   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; 4 METHYLPYRAZOLE; 5BETA CHOLANIC ACID 3ALPHA, 7ALPHA DIOL; ALCOHOL DEHYDROGENASE; ALDO KETO REDUCTASE; CARBONYL REDUCTASE; CELL ENZYME; CHOLANIC ACID DERIVATIVE; DICOUMAROL; ETACRYNIC ACID; FLUFENAMIC ACID; INDOMETACIN; MEDROXYPROGESTERONE ACETATE; MENADIONE; METHYL 6ALPHA NALTREXOL; METHYL 6BETA NALTREXOL; METHYLNALTREXONE SULFATE; NALTREXOL; NALTREXONE; PHENOBARBITAL; PHENOLPHTHALEIN; QUERCETIN; QUINONE OXIDOREDUCTASE; SULFOTRANSFERASE; SULFOTRANSFERASE 1E1; SULFOTRANSFERASE 2A1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOSOL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SULFATION;

ALCOHOL OXIDOREDUCTASES; ANIMALS; BIOCATALYSIS; CYTOSOL; DOGS; ENZYME INHIBITORS; ENZYMES; HAPLORHINI; HUMANS; KINETICS; LIVER; MASS SPECTROMETRY; MICE; MOLECULAR STRUCTURE; NADP; NALTREXONE; OXIDATION-REDUCTION; OXIDOREDUCTASES; QUATERNARY AMMONIUM COMPOUNDS; RATS; RECOMBINANT PROTEINS; SULFOTRANSFERASES; SULFURIC ACID ESTERS;

EID: 77950925561     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032169     Document Type: Article

References (32)

1. Atalla A, Breyer-Pfaff U, and Maser E (2000) Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica 30:755-769.
2. Atalla A and Maser E (2001) Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact 130-132:737-748. (Pubitemid 32295859)
3. Bauman DR, Rudnick SI, Szewczuk LM, Jin Y, Gopishetty S, and Penning TM (2005) Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol 67:60-68.
4. Breyer-Pfaff U and Nill K (2004) Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol 56:1601-1606. (Pubitemid 39602003)
5. Brown DR and Goldberg LI (1985) The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24:181-191.
6. Chandrasekaran A, Tong Z, Li H, Erve J, DeMaio W, Goljer I, McConnell O, Rotshteyn Y, Hultin T, Talaat R, et al. (2010) Metabolism of intravenous methylnaltrexone in mice, rats, dogs and humans. Drug Metab Dispos doi: 10.1124/dmd.109.031179.
7. El-Kabbani O, Wilson DK, Petrash M, and Quiocho FA (1998) Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Mol Vis 4:19.
8. Fayz S and Inaba T (1998) Zidovudine azido-reductase in human liver microsomes: activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 42:1654-1658. (Pubitemid 28311557)
9. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, and McManus ME (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-22. (Pubitemid 43264722)
10. Gebel T and Maser E (1992) Characterization of carbonyl reducing activity in continuous cell lines of human and rodent origin. Biochem Pharmacol 44:2005-2012.
11. Huang MT, Chang RL, Fortner JG, and Conney AH (1981) Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. J Biol Chem 256: 6829-6836.
12. Jez JM, Bennett MJ, Schlegel BP, Lewis M, and Penning TM (1997) Comparative anatomy of the aldo-keto reductase superfamily. Biochem J 326:625-636. (Pubitemid 27438032)
13. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, and White SA (2004) Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res 64:1802-1810.
14. Maser E, Stinner B, and Atalla A (2000) Carbonyl reduction of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett 148:135-144. (Pubitemid 30047100)
15. Matsunaga T, Shintani S, and Hara A (2006) Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet 21:1-18.
16. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, and Ratnam K (2000) Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1- AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67-77.
17. Porter SJ, Somogyi AA, and White JM (2000) Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 50:465-471.
18. Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, and Walsh JS (2004) Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 147:129-139. (Pubitemid 38324542)
19. Rosemond MJ and Walsh JS (2004) Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 36:335-361.
20. Sanli G, Dudley JI, and Blaber M (2003) Structural biology of the aldo-keto reductase family of enzymes: catalysis and cofactor binding. Cell Biochem Biophys 38:79-101. (Pubitemid 41282441)
21. Schwab GE, Raucy JL, and Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493-499.
22. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455. (Pubitemid 24189354)
23. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, and Penning TM (2004) Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 279:10784-10795. (Pubitemid 38379543)
24. Steckelbroeck S, Oyesanmi B, Jin Y, Lee SH, Kloosterboer HJ, and Penning TM (2006) Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. J Pharmacol Exp Ther 316:1300-1309.
25. Urzhumtsev A, Tête-Favier F, Mitschler A, Barbanton J, Barth P, Urzhumtseva L, Biellmann JF, Podjarny A, and Moras D (1997) A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 5:601-612.
26. Wall ME, Brine DR, and Perez-Reyes M (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 9:369-375.
27. Wall ME, Perez-Reyes M, Brine DR, and Cook CE (1984) Naltrexone disposition in man after subcutaneous administration. Drug Metab Dispos 12:677-682.
28. Yuan CS, Foss JF, O'Connor M, Moss J, and Roizen MF (1998) Gut motility and transit changes in patients receiving long-term methadone maintenance. J Clin Pharmacol 38:931-935.
29. Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, and Roizen MF (2000) Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283:367-372.
30. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, and Moss J (1999) Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 83:631-635.
31. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, and Moss J (1996) Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59:469-475.
32. Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, and Osinski J (2002) Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a doubleblind randomized placebo-controlled trial. J Pharmacol Exp Ther 300:118-123.